术后计算机体层摄影无残留病灶对初次手术达到最佳减瘤的晚期高级别浆液性卵巢癌患者生存的影响
该研究纳入2013至2018年间初次减瘤术后残留病灶小于1厘米的III期高级别浆液性卵巢癌患者436例,按手术评估(sR0/sR1)与术后CT评估(rR0/rRany)分组。多因素分析显示,术前CT有腹水、sR0/rRany组和sR1/rRany组与较差的无进展生存和总生存相关。作者认为手术联合影像评估残留病灶大小比仅手术评估更能准确预测生存。
要点
- 术后CT评估残留病灶与手术评估不一致者占40.4%(176/436例)。
- sR0/rRany组和sR1/rRany组与较差的无进展生存和总生存相关。
- 术前CT有腹水也与较差的无进展生存和总生存相关。
核心结论
- 对于初次减瘤术后残留病灶小于1厘米的晚期卵巢癌患者,联合手术和影像学评估残留肿瘤大小比仅手术评估更能准确预测生存。
研究设计与样本
- 回顾性收集2013至2018年间III期高级别浆液性卵巢癌初次减瘤术后残留病灶小于1厘米的患者数据,共436例。
- 手术评估残留病灶分为sR0(无肉眼残留)和sR1(肉眼残留小于1厘米),术后CT影像评估分为rR0(无疾病证据)和rRany(存在残留病灶)。
- 将患者分为sR0/rR0、sR1/rR0、sR0/rRany和sR1/rRany四组。
主要发现
- sR0/rR0组187例(42.9%),sR1/rR0组59例(13.5%),sR0/rRany组79例(18.1%),sR1/rRany组111例(25.5%)。
- 手术与影像评估不一致者176例(40.4%),其中38例为sR1/rRany组且两种方法指示的残留肿瘤位置不一致。
- 多因素分析显示,术前CT有腹水、sR0/rRany组和sR1/rRany组与较差的无进展生存和总生存相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to investigate the impact of size of residual tumors as determined by postoperative computed tomography (CT) on survival of patients with advanced, high-grade serous ovarian carcinoma (HGSC) who achieved residual disease less than 1 cm after primary debulking surgery (PDS). METHODS: We collected data of patients with stage III HGSC who had residual tumor less than 1 cm after PDS between 2013 and 2018. Surgeon-assessed residual disease during surgery was defined as sR0 (no gross residual) or sR1 (gross residual <1 cm), and radiologist-assessed residual disease on postoperative CT was defined as rR0 (no evidence of disease) or rRany (existing residual disease). All patients were classified into the following groups: sR0/rR0, sR1/rR0, sR0/rRany, and sR1/rRany. RESULTS: A total of 436 patients was placed into the sR0/rR0 (n = 187, 42.9%), sR1/rR0 (n = 59, 13.5%), sR0/rRany (n = 79, 18.1%), or sR1/rRany group (n = 111, 25.5%). Discrepancies between surgical and radiological assessments were recorded for 176 patients (40.4%) including 38 cases of sR1/rRany group with discordant residual tumor location indicated between two methods. During multivariate analysis, patients with ascites on preoperative CT, sR0/rRany group inclusion, and sR1/rRany group inclusion showed unfavorable progression-free and overall survival. CONCLUSIONS: The incorporation of surgical and radiological evaluations for determining the size of residual tumors was more accurate than surgical evaluation only for predicting survival among patients with advanced ovarian cancer who underwent PDS to residual disease less than 1 cm.
引用
- Lim H, In Shim J, Park SJ, et al. Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. Gynecol Oncol. 2022. PMID: 35367074. doi:10.1016/j.ygyno.2022.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。